February 06, 2017

Pluristem Therapeutics Receives FDA Approval

Great news: Our client Pluristem Therapeutics Inc. received the FDA's approval for phase 3 of its PLX-PAD cells study. http://bit.ly/2ijOr3M

Thomas Heinzen, Cryoport, Inc

Stem Cells Could Treat Meniscal Tears

According to researchers, stem cell therapy could possibly help treat those who suffer from meniscal tears. http://bit.ly/2jc6ayC

Feb 06, 2017

Thomas Heinzen, Cryoport, Inc

Moffitt Cancer Center Selects Cryoport as Its Exclusive Cryogenics Logistics Provider

Learn more: http://bit.ly/2hclGdN

Jan 23, 2017

Thomas Heinzen, Cryoport, Inc

Fred Hutchinson Cancer Research Center Shares Highlights from American Society of Hematology Conference

Fred Hutchinson Cancer Research Center discusses the exciting future of CAR T-cell therapy, where cryogenic logistics are essential, at the 2016 American Society of Hematology annual conference. http://bit.ly/2hZgkSB

Jan 23, 2017

Thomas Heinzen, Cryoport, Inc

Cryoport's CCO Discusses Challenges In The Cold Chain Industry

Cryoport CCO Mark Sawicki shares in an interview with OutSourcing-Pharma the upcoming challenges that the cold chain industry will be facing. Read here: http://bit.ly/2gzwkGG

Jan 05, 2017

Thomas Heinzen, Cryoport, Inc

BBC News Call Immunotherapy a 'Game Changer'

Immunotherapy has become a 'game changer' for many cancer patients via BBC News. Learn more: http://bbc.in/2gGNxBO

Jan 05, 2017

Thomas Heinzen, Cryoport, Inc

Regenerative Medicine and Stem Cell Therapies Continue Progress For Potential Disease Treatments

Regenerative medicine and stem cell therapies continue to move in a positive direction for potential disease treatments. Learn more: http://bit.ly/2fR4EzQ

Jan 04, 2017

Thomas Heinzen, Cryoport, Inc

The Washington Post Names Immunotherapy 'Hottest' Field In Cancer Treatments

Learn why: http://wapo.st/2geltWi

Jan 04, 2017

Thomas Heinzen, Cryoport, Inc

Fred Hutchinson Cancer Research Center Grand Opening

Fred Hutchinson Cancer Research Center officially opened a first-of-its-kind clinic to provide immunotherapy for cancer patients in clinical trials. Learn more: http://bit.ly/2gfgguU

Jan 04, 2017

Thomas Heinzen, Cryoport, Inc

FDA Approves Immunotherapy For Cancer Patients

The FDA approved immunotherapy, giving many cancer patients hope. Learn more: http://bit.ly/2fbwHcs

Jan 03, 2017

Thomas Heinzen, Cryoport, Inc

Cryoport Client ImmunoCellular Therapeutics' Stock Price Is Rising

After new clinical trial data, our client ImmunoCellular Therapeutics’ stock price is reacting very positively! Here about how Cryoport supports ImmunoCellular: http://bit.ly/2gdS8Jc

Jan 03, 2017

Thomas Heinzen, Cryoport, Inc

FDA Approves Immunotherapy For Cancer Patients

The FDA approved immunotherapy, giving many cancer patients hope. Learn more: http://bit.ly/2fbwHcs

Dec 27, 2016

Thomas Heinzen, Cryoport, Inc

Cryoport Client ImmunoCellular Therapeutics' Stock Price is Rising

After new clinical trial data, our client ImmunoCellular Therapeutics’ stock price is reacting very positively! Here about how Cryoport supports ImmunoCellular: http://bit.ly/2gdS8Jc

Dec 27, 2016

Thomas Heinzen, Cryoport, Inc

Technavio Predicts The Global Cryogenic Freezers Market To Grow at a CAGR of 8.17% until 2019.

http://bit.ly/2e6fSkk

Dec 19, 2016

Thomas Heinzen, Cryoport, Inc

Regenerative Medicine Market To Grow At A CAGR of 33%

Analysts expect the regenerative medicine market to grow at a CAGR of 33%+ due to stem cell product demand via @medgadget http://bit.ly/2etQiTx

Dec 16, 2016

Thomas Heinzen, Cryoport, Inc

Heart Stem Cell Transplant Success

A primate heart stem cell transplant successfully induced cardiac self-repair in another primate. Read more from Futurism. http://bit.ly/2dryYkP

Dec 16, 2016

Thomas Heinzen, Cryoport, Inc

Cryoport Named A Top Performer

Cryoport was one of the best performers among all companies listed in the consumer goods sector on the NYSE and NASDAQ exchanges during trading. Read why here: http://bit.ly/2eexkPA

Dec 16, 2016

Thomas Heinzen, Cryoport, Inc

AICD-Resistant Tcells Improve Therapeutic Outcome

New study shows AICD-resistant tcells improve therapeutic outcome by increasing tcell persistence and tumor control. Learn more: http://bit.ly/2dDX4qL

Dec 16, 2016

Thomas Heinzen, Cryoport, Inc

The Global Regenerative Medicines Market Is Expected To Reach USD 50.11 Billion By 2021

Learn more: http://bit.ly/2edYcij

Dec 10, 2016

Thomas Heinzen, Cryoport, Inc

Cryoport Can Prevent An Interruption In Supply Chain

Variation in temp or interruption in supply chain can delay delivery & administration of therapy to the patient. Cryoport prevents this: http://bit.ly/2e7jz5G

Dec 10, 2016

Thomas Heinzen, Cryoport, Inc

Trust Cryoportal

$1.9 trillion of economic value could be created by asset tracking solutions like Cryoportal. BusinessInsider writes: http://read.bi/2e6Lw0R

Dec 10, 2016

Thomas Heinzen, Cryoport, Inc

U.S. Department of Commerce Estimates The Global Figure At $130 billion For Healthcare Products

U.S. Department of Commerce estimates the global figure at $130 billion for healthcare products, which rely on cold chain logistics to ensure integrity according to @Enterprisei. Learn more: http://bit.ly/2dio5h3

Dec 08, 2016

Thomas Heinzen, Cryoport, Inc

U.S. Department of Commerce Estimates The Global Figure At $130 billion For Healthcare Products

Dec 08, 2016

Thomas Heinzen, Cryoport, Inc

Cryoport Integrated Solution

Cryoport’s integrated solution reduced the incidence of carrier mishandling events for a client from 32 to zero. The client’s clinical trials are continuing without shipper orientation issues. Check out the whole case study here: http://bit.ly/IMcyr2

Dec 08, 2016

Thomas Heinzen, Cryoport, Inc

Cryoport Addresses Risks During Shipping

Cryoport addresses risks during shipment by working with trusted shipping partners and equipping each shipment with a SmartPak II™ condition monitoring . http://bit.ly/2dhzSxL

Dec 07, 2016